Integrated Data Analytics and Reporting, Janssen Research and Development, Graaf Engelbertlaan 75, 4837DS, Breda, Netherlands.
Development Operations, AstraZeneca R&D BioPharmaceuticals, ul. Postepu 14, 02-675, Warsaw, Poland.
Ther Innov Regul Sci. 2023 Jul;57(4):839-848. doi: 10.1007/s43441-023-00504-6. Epub 2023 Mar 27.
Since the release of ICH E6(R2), multiple efforts have been made to interpret the requirements and suggest ways of implementing quality tolerance limits (QTLs) alongside existing risk-based quality management methodologies. While these efforts have contributed positively to developing a common understanding of QTLs, some uncertainty remains regarding implementable approaches. In this article, we review the approaches taken by some leading biopharmaceutical companies, offering recommendations for how to make QTLs most effective, what makes them ineffective, and several case studies to illustrate these concepts. This includes how best to choose QTL parameters and thresholds for a given study, how to differentiate QTLs from key risk indicators, and how QTLs relate to critical-to-quality factors and the statistical design of the trials.
自 ICH E6(R2) 发布以来,已经做出了多项努力来解释这些要求,并提出了在现有的基于风险的质量管理方法的基础上实施质量公差限度(QTL)的方法。虽然这些努力对发展对 QTL 的共同理解有积极的贡献,但在实施方法方面仍存在一些不确定性。在本文中,我们回顾了一些领先的生物制药公司所采取的方法,为如何使 QTL 最有效、哪些因素使它们无效以及几个案例研究提供了建议,以说明这些概念。这包括如何为特定的研究选择 QTL 参数和阈值,如何区分 QTL 和关键风险指标,以及 QTL 与关键质量因素和试验的统计设计的关系。